Company Description
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
The company’s lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2.
Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021.
The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020.
The company was incorporated in 2019 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Joseph Ferra |
Contact Details
Address: 101 Federal Street, Suite 1900 Boston, Massachusetts 02110 United States | |
| Phone | 716 371 1125 |
| Website | elevationoncology.com |
Stock Details
| Ticker Symbol | ELEV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001783032 |
| CUSIP Number | 28623U101 |
| ISIN Number | US28623U1016 |
| Employer ID | 84-1771427 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Joseph J. Ferra Jr. | Chief Executive Officer, President and Director |
| Valerie Malyvanh Jansen M.D., Ph.D. | Chief Medical Officer |
| Tammy Furlong CPA, P.M.P. | Chief Financial Officer and Secretary |
| Robert C. Yang | Senior Vice President and General Counsel |
| Ryan Bloomer | Senior Vice President of Technical Operations |
| Biren Shah | Senior Vice President of Business and Corporate Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | SCHEDULE 13G | Filing |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 6, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Feb 4, 2025 | SCHEDULE 13G | Filing |